|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Chicago National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00023946 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer.
| Condition | Intervention | Phase |
|
Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer |
Drug: ixabepilone |
Phase II |
| MedlinePlus related topics: | Cancer Liver Cancer |
| ChemIDplus related topics: | Epothilone B Ixabepilone |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer |
| Study Start Date: | October 2001 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 weeks until disease progression.
PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 14 months.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed locally advanced, metastatic, or recurrent hepatobiliary cancer
At least 1 unidimensionally measurable lesion
The following are not considered measurable lesions:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations| United States, California | |||||
| USC/Norris Comprehensive Cancer Center and Hospital | |||||
| Los Angeles, California, United States, 90033 | |||||
| United States, Illinois | |||||
| Cardinal Bernardin Cancer Center at Loyola University Medical Center | |||||
| Maywood, Illinois, United States, 60153 | |||||
| Central Illinois Hematology Oncology Center | |||||
| Springfield, Illinois, United States, 62701 | |||||
| La Grange Memorial Hospital | |||||
| La Grange, Illinois, United States, 60525 | |||||
| Evanston Northwestern Health Care - Evanston Hospital | |||||
| Evanston, Illinois, United States, 60201-1781 | |||||
| Ingalls Cancer Care Center at Ingalls Memorial Hospital | |||||
| Harvey, Illinois, United States, 60426 | |||||
| Decatur Memorial Hospital Cancer Care Institute | |||||
| Decatur, Illinois, United States, 62526 | |||||
| Louis A. Weiss Memorial Hospital | |||||
| Chicago, Illinois, United States, 60640 | |||||
| Oncology/Hematology Associates of Central Illinois, P.C. | |||||
| Peoria, Illinois, United States, 61615-7828 | |||||
| University of Chicago Cancer Research Center | |||||
| Chicago, Illinois, United States, 60637-1470 | |||||
| University of Illinois Medical Center | |||||
| Chicago, Illinois, United States, 60612 | |||||
| United States, Indiana | |||||
| Fort Wayne Medical Oncology and Hematology, Incorporated | |||||
| Fort Wayne, Indiana, United States, 46885-5099 | |||||
| Michiana Hematology-Oncology, P.C. - South Bend | |||||
| South Bend, Indiana, United States, 46601 | |||||
| United States, Michigan | |||||
| Oncology Care Associates, P.L.L.C. | |||||
| Saint Joseph, Michigan, United States, 49085 | |||||
| University of Chicago |
| National Cancer Institute (NCI) |
| Study Chair: | Hedy L. Kindler, MD | University of Chicago |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000068878, UCCRC-11045, NCI-3656 |
| First Received: | September 13, 2001 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00023946 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|